BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PSMA ADC: Preliminary Phase I data

Preliminary data from an ongoing, open-label, dose-escalation, U.S. Phase I trial in 21 patients with metastatic HRPC previously treated with taxane-based chemotherapy regimens showed that 4 doses of 0.4-1.8 mg/kg IV PSMA ADC every 3 weeks for 12 weeks were well tolerated. The most common adverse...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >